» Articles » PMID: 39403422

A Case of Plasma Cell Leukemia Arising De Novo: A Rare and Fatal Disease

Overview
Journal Cureus
Date 2024 Oct 15
PMID 39403422
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma cell leukemia (PCL) is an aggressive form of multiple myeloma characterized by an increasing number of circulating plasma cells in the peripheral (circulating) blood. Primary PCL (pPCL) is the form of monoclonal gammopathy that is the most severe with a high mortality rate. Its incidence will be increasing, given the expected changes in clinical criteria for diagnosis. We present a case to help further understand the disease and the proposed criteria changes, as more research will be needed to better understand the impact of specific genetic findings on the prognosis of pPCL and secondary PCL (sPCL). We also feature the presentation, morphological changes in the peripheral smear, and cytogenetics of this rare disease.

References
1.
Tiedemann R, Gonzalez-Paz N, Kyle R, Santana-Davila R, Price-Troska T, Van Wier S . Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008; 22(5):1044-52. PMC: 3893817. DOI: 10.1038/leu.2008.4. View

2.
Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D . Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009; 115(24):5734-9. DOI: 10.1002/cncr.24700. View

3.
Finnegan D, Kettle P, Drake M, Matthews C, Alexander H, Popat R . Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma. 2006; 47(8):1670-3. DOI: 10.1080/10428190500520954. View

4.
Blade J, Kyle R . Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 2000; 13(6):1259-72. DOI: 10.1016/s0889-8588(05)70125-8. View

5.
Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N . European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018; 32(9):1883-1898. DOI: 10.1038/s41375-018-0209-7. View